The LUNAR trial is intended for patients who have recently been diagnosed with progression of non-small cell lung cancer (NSCLC) during or after first line of therapy. This clinical trial is evaluating the safety and efficacy of the NovoTTF-100L System for use in NSCLC, when added to either a PD-1 inhibitor or docetaxel which are normally given to patients in this condition. The NovoTTF-100L System delivers Tumor Treating Fields (TTFields) to the cancer in the chest. Novocure Ltd., the trial sponsor, maintains this website to help patients get basic information about this clinical trial and facilitate their accessibility to medical centers that offer participation in this trial. If you would like to take part in the LUNAR trial, please contact one of the participating centers as soon as possible. If you have questions concerning your medical condition and recommended treatment, please consult with your treating doctor.